

CURRICULUM VITAE- Nasrollah Erfani, PhD

Last Update: January 20, 2024



Surname: Erfani

First Name: Nasrollah

Current Position: Professor of Immunology

Affiliation:

Cancer Immunology & Immunotherapy Lab, Head

Department of Immunology

School of Medicine

Shiraz university of medical sciences

P.O. Box: 71345-1798

Shiraz-Iran

Tel/Fax: +98(0)71 32351557

Joint Affiliation:

Cancer Immunology & Immunotherapy Group, Head

Shiraz Institute for Cancer Research (ICR)

Shiraz University of Medical Sciences

P.O. Box: 71345-3119

Shiraz-Iran

Tel: +98(0)71 32303687, **Fax:** +98(0)71 32304952

E-mail: erfanin@sums.ac.ir;

erfani52@gmail.com

Profile/ID at the authors profiles systems:

- Scopus author ID: 8663943500
URL: <http://www.scopus.com/authid/detail.url?authorId=8663943500>
- Web of Science ResearcherID: C-9376-2011
URL: <https://www.webofscience.com/wos/author/record/1706839>
- Google scholar profile:
URL: http://scholar.google.com/citations?user=be_ss0oAAAAJ&hl=en
- Open Researcher & Contributor ID (ORCID): 0000-0002-4158-9128
URL: <http://orcid.org/0000-0002-4158-9128>
- ISID: http://isid.research.ac.ir/Nasrollah_Erfani

Profile at the academic social networks:

- **Academia:** <http://sums.academia.edu/NasrollahErfani>
- **Research Gate:** http://www.researchgate.net/profile/Nasrollah_Erfani/
- **Linked in:** www.linkedin.com/in/nasrollah-erfani-bb4a8549

Citation Metrics up to January 20, 2024:

- **Scopus:** Total citations: 2181, H-index: 28, G-index: 42
- **Web of Science:** Total citations: 1879, H-index: 25, G-index: 39
- **Google Scholar:** Total citations: 3042, H-index: 33, G-index: 51, i10 index: 69

University appointment:

- Ⓒ Professor of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran, 2017–present
- Ⓒ Associate Professor of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran, 2012 – 2017
- Ⓒ Assistant Professor of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran, 2008-2012

Qualifications and trainings

- Ⓒ Ph.D. in Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 2002 – 2008
- Ⓒ Sabbatical during PhD (Scholarship from Iran's Ministry of Health and Medical Education): Cancer Proteomics, Joint proteomics laboratory (JPSL), Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Australia, April 2006- November 2006
- Ⓒ M.Sc. in Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 1999 – 2002
- Ⓒ B.Sc. in Biology, Faculty of Sciences, Razi University, Kermanshah, Iran, 1992-1996

Fellowships:

- Research fellowship, Shiraz University of Medical Sciences, Shiraz, Iran, 2013
- E-learning fellowship, Shiraz University of Medical Sciences, Shiraz, Iran, April to September 2012
- Medical education fellowship, Shiraz University of Medical Sciences, Shiraz, Iran, from November to December 2011

Distinction, honors and awards

- Selected as the distinguished professor in 2021, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 2021
- Winner of 2019-2020 German-Iranian BMBF-SMRT mobility grant to perform a joint research study on cancer immune-cell therapy with Technical University (TU) Dresden, Germany, 2019- now
- Winner of the best-abstract award of the 8th annual meeting of Asian Cell Therapy Organization (ACTO), Beijing, China, 2017
- Top researcher of the research centers, Shiraz University of Medical Sciences, Shiraz, Iran, 2016
- Top researcher of the Fars province, Shiraz, Iran, 2015
- Honor postgraduate student of the University, Shiraz University of Medical Sciences, Years 2004 & 2005 & 2006
- Member of "Gifted Talent Office" during PhD study at Shiraz University of Medical Sciences, Shiraz, Iran
- Winer of the scholarship for PhD study offered by Shiraz University of Medical Sciences, Shiraz, Iran: 2003-2008

- First rank promoted in PhD written entrance-exam in Immunology, Iran's Ministry of health and medical education. 2002
- Honor MSc student of Immunology, Shiraz University of Medical Sciences, 2001

Administrations

- Vice chancellor (VC) for International Affairs, Shiraz University of Medical Sciences, Shiraz, Iran, February 2015–April 2022 (Stablishing the VC and holding the position for more than 7 years)
- Vice Director, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran, 2008-now
- Head of Cancer Immunology and Immunotherapy Group, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran, 2008-now
- Head of “Unrelated stem cell donor registry unit” and “bone marrow transplantation (BMT) HLA bank”, Shiraz University of Medical Sciences, January 2022-Now
- Head of “Faculty-member Affairs of the Research Centers”, Shiraz University of Medical Sciences, 2011–2019 March
- Manager of “Scientific Resources and Medical Informatics”, Shiraz University of Medical Sciences, Shiraz, Iran, 2014–2015
- Head of the “Research laboratories for the advanced medical technologies”, Shiraz University of Medical Sciences, Shiraz, Iran, 2013–2015

Membership

- Member of the Iranian Immunology Board, March 2019-now
- Secretary General, and the member of the directory board of the Iranian Society for Immunology & Allergy (ISIA); (<http://isiaonline.org/>), August 2021-now
- Member of The Federation of Immunological Societies of Asia-Oceania (FIMSA; <http://www.fimsa.org/>), which is itself a member of International Union of Immunological Societies (IUIS; <https://iuis.org/>)
- Member of European Association for Cancer Research (EACR; <https://www.eacr.org/>), Membership Number: EACR30067
- Member of The Association for Cancer Immunotherapy (CIMT; <https://www.cimt.eu/>), Germany, Member Number: E121
- Member of the Iranian Proteomics Society (<http://www.proteomics.ir/>)
- Member of the stirring committee, Iran's Cancer Research Network (March 2011-now)
- Head of the university international council, Shiraz University of Medical Sciences, Shiraz Iran, February 2015–April 2022
- Member of the university research council, Shiraz University of Medical Sciences, Shiraz Iran, June 2013-now
- Member of the university higher-education council, Shiraz University of Medical Sciences, Shiraz Iran, 2013- 2015

Scientific fields of interest

My main scientific field of interest is Cancer Immunology and Immune Cell Therapy. Performing applied research on autologous/allogenic Natural Killer (NK) Cells or engineered (e.g. CAR-) NK cells for cancer immunotherapy is among hot research topics at my research laboratory. Experimental study of anti-cancer immune responses, consultation for

immunoassay/vaccine development and the study of the biologic effects of novel drug candidates are among other research activities that are carried out at my research Lab.

Teaching Experiences

- Teaching Immunology to the **students of Medicine (MD), Dentistry (DDM), Pharm D. and post graduate clinical programs**, Shiraz university of Medical sciences, Shiraz, Iran, 2008-now
- Teaching Immunology to the international students of **International Education Programs (IEPs)**, Shiraz university of Medical sciences, Shiraz, Iran (The language of instruction in IEP program is English). 2015-now
- Teaching Advanced Immunology, Applied Immunology, Immunogenetics, Immunotherapy, Immune cell therapy, Targeted therapy, Vaccines, Immunochimistry and Immunological Methods, Flowcytometry, Molecular diagnosis, DNA sequencing and different topics in molecular medicine to **MSc and PhD student**, School of Medicine as well as the Graduate school of advanced medical sciences and technologies, Shiraz university of Medical sciences, Shiraz, Iran, 2008-now
- Teaching advanced Immunology, Molecular Biology of Tumors, etc. to the **students of Phd-by-research programs**, Shiraz university of Medical sciences, Shiraz, Iran, 2011-now

Thesis supervision

- Supervising and/or advising more than 68 graduate (PhD, MSc, Specialty and sub-specialty) and undergraduate (MD, Pharm D or DDM) students' thesis. 2008-now

Research projects

Currently working as the head of Cancer Immunology and Immunotherapy Research Group at the Department of Immunology, as well as the Shiraz Institute for Cancer Research (ICR), Shiraz University of Medical Sciences, Shiraz, Iran.

- In collaboration with international partners, Cancer Immune Cell Therapy is the main field of study in my Lab. Following projects are in progress or have already been accomplished in this field:
 - Autologous NK cell therapy trial in collaboration with a Japanese party (Preclinical phase and clinical trial Phase 1)
 - Chimeric Antigen Receptor (CAR)-NK cells targeting TAAs as well as cancer-associated immune-inhibitory receptors for the purpose of cancer immunotherapy; two separate projects are now in progress; of which one is in collaboration with Technical University (TU) Dresden in Germany
- The main goals of the other projects undertaken in my Lab are:
 - Th17 and Regulatory T cells in cancer, new concepts and therapeutic applications
 - Investigation of the immune response inhibitory state in patients with cancers
 - Assessment of In-vitro anti-tumoral activity as well as immune effects of anticancer loaded nano/micro-particles and newly designed therapeutic agents

- Cancer Proteomics; biomarkers for screening, therapy and vaccine design
- Molecular analysis of the immune-related genes in patients with cancers
- Cancer Bio-bank in southern Iran

Publications

Symbols: *corresponding author, #The same contribution as the first author

1. Asadi M, Kiani R, Razban V, Faraji SN, Ahmadi A, Fallahi J, Ramezani A. **Erfani N***. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies. *Iran J Immunol.* 2023;20(4):410-26. DOI: <https://doi.org/10.22034/iji.2023.100424.2691>
2. Farahani H, Dehghanian AR, Khademolhosseini A, Haghshenas MR, **Erfani N***. Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma. *J Reprod Immunol.* 2023; 161:104184. DOI: <https://doi.org/10.1016/j.jri.2023.104184>
3. Aliabadi A, Haghshenas MR, Kiani R, Koohi-Hosseiniabadi O, Purkhosrow A, Pirsalami F, Panjehshahin, MR. **Erfani N***. In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning. *Naunyn Schmiedebergs Arch Pharmacol.* 2023, In press. DOI: <https://doi.org/10.1007/s00210-023-02722-z>
4. Hashemi S, Seradj H, Kiani R, Jassbi AR, **Erfani N***. Two Ursane Triterpenoids of *Salvia urmiensis* Induce Apoptosis and Cell Cycle Arrest in Human Lung Carcinoma Cells. *Pharmaceutical Sciences,* 2023; 29(2):190-199. DOI: <https://doi.org/10.34172/PS.2022.32>
5. Gerdabi S, Asadian F, Kiani R, Khademi B, Haghshenas MR, Erfani N*. Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment. *Head Neck Pathol.* 2023;17(1):178-92. DOI: <https://doi.org/10.1007/s12105-022-01486-x>
6. Salmanpour A, Rezaeifard S, Kiani R, Tahmasebi S, Faghieh Z, **Erfani N***. IFN γ -IL-17-IL-22+CD4+ subset and IL-22-producing cells in tumor draining lymph nodes of patients with breast cancer. *Breast Dis.* 2022;41(1):383-90. DOI: <https://doi.org/10.3233/BD-210084>
7. Haghshenas MR, **Erfani N**, Khansalar S, Khademi B, Ashraf MJ, Razmkhah M, et al. Proteomics Study of Mesenchymal Stem Cell-Like Cells Obtained from Tumor Microenvironment of Patients with Malignant and Benign Salivary Gland Tumors. *Cell J.* 2022;24(4):196-203. DOI: <https://doi.org/10.22074/cellj.2022.7844>
8. Saadati Z, Haghshenas MR, Rezaeifard S, Heidari F, **Erfani N***. Reference Ranges of Lymphocyte Subsets in Healthy Individuals from Southern Iran. *Clin Lab.* 2022;68(10). DOI: <https://doi.org/10.7754/Clin.Lab.2022.211245>
9. Heidari F, Ramezani A, **Erfani N**, Razmkhah M. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related

10. Dabbaghmanesh MH, Rezaei B, Haghshenas MR, Montazeri-Najafabady N, Amiri RM, *Erfani N*.* CCR4 1014C/T and CCL22 16C/A Genetic Variations in teh Iranian Patients with Thyroid Cancer. *Middle East J Cancer.* 2022;13(3):404-10. DOI: <https://doi.org/10.30476/MEJC.2021.87469.1421>
11. Rezaeifard S, Talei A, Shariat M, *Erfani N*.* Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer. *Mol Immunol.* 2021;136:161-7. DOI: <https://doi.org/10.1016/j.molimm.2021.03.003>
12. Rezaeifard S, Heike Y, Masuyama JI, Rezvani A, Vojdani R, *Erfani N**. Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience. *Iran J Allergy Asthma Immunol.* 2021;20(2):233-43.URL: <https://www.ncbi.nlm.nih.gov/pubmed/33904681>
13. Maleksabet A, Zarei Jaliani H, Asgari A, Ramezani A, *Erfani N*.* Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells. *Iranian journal of medical sciences.* 2021;46(4):281-90. DOI: <https://doi.org/10.30476/ijms.2020.83234.1219>
14. Heidari F, Razmkhah M, Razban V, *Erfani N*. Effects of indoleamine 2, 3-dioxygenase (IDO) silencing on immunomodulatory function and cancer-promoting characteristic of adipose-derived mesenchymal stem cells (ASCs). *Cell Biol Int.* 2021;45(12):2544-56. DOI: <https://doi.org/10.1002/cbin.11698>
15. Hashemi S, Jassbi AR, *Erfani N*, Kiani R, Seradj H. Two new cytotoxic ursane triterpenoids from the aerial parts of *Salvia urmiensis* *Bunge*. *Fitoterapia.* 2021;154:105030. DOI: <https://doi.org/10.1016/j.fitote.2021.105030>
16. Faghieh Z, Taherifard E, Daneshmand A, Talei A, *Erfani N*.* OX40 genetic variations in patients with breast cancer: a case-control study. *Br J Biomed Sci.* 2021;78(1):44-6. DOI: <https://doi.org/10.1080/09674845.2020.1776587>
17. Dorosti H, Nezafat N, Heidari R, Ghoshoon MB, Gholami A, Dehshahri A, *Erfani N*, et al. Production and Immunological Evaluation of Epitope-based Preventative Pneumococcal Candidate Vaccine Comprising Immunodominant Epitopes from PspA, CbpA, PhtD and PiuA Antigens. *Curr Pharm Biotechnol.* 2021;22(14):1900-9. DOI: <https://doi.org/10.2174/1389201022666201231112029>
18. Aslani A, Haghshenas MR, *Erfani N*, Khezri AA. IL17A and IL17F genetic variations in iranian patients with urothelial bladder cancer: A case-control study. *Middle East J Cancer.* 2021;12(3):377-82. DOI: <https://doi.org/10.30476/mejc.2021.83915.1185>
19. Asadi M, Ahmadi N, Ahmadvand S, Jafari AA, Safaei A, *Erfani N*, et al. Investigation of olfactory receptor family 51 subfamily j member 1 (OR51J1) gene susceptibility as a potential breast cancer-associated biomarker. *PLoS One.* 2021;16(2):e0246752. DOI: <https://doi.org/10.1371/journal.pone.0246752>

20. Vakili B, Nezafat N, Zare B, *Erfani N*, Akbari M, Ghasemi Y, et al. A new multi-epitope peptide vaccine induces immune responses and protection against *Leishmania infantum* in BALB/c mice. *Med Microbiol Immunol*. 2020;209(1):69-79. DOI: <https://doi.org/10.1007/s00430-019-00640-7>
21. Rasoolian M, Hosseini SY, Khanahmad H, Sarvari J, Rahbarizadeh F, Amani AM, *Erfani N*, et al. Gene Delivery by Pei-Nanocomplex Into Breast and Colorectal Tumor Cell Lines, the Impacts of N/P Ratio, Size and Type of the Cell. *FABAD Journal of Pharmaceutical Sciences*. 2020;45(1):19-27. URL: <https://search.proquest.com/docview/2386339324?accountid=41313>
22. Negahdaripour M, Nezafat N, Heidari R, *Erfani N*, Hajighahramani N, Ghoshoon MB, et al. Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine. *Curr Pharm Biotechnol*. 2020;21(4):316-24. DOI: <https://doi.org/10.2174/1389201020666191114104850>
23. Keshtgar S, Ebrahimi B, Shid-Moosavi SM, *Erfani N*. NADPH oxidase 5 activation; a novel approach to human sperm cryoinjury. *Cell Tissue Bank*. 2020;21(4):675-84. DOI: <https://doi.org/10.1007/s10561-020-09845-0>
24. Ariafar A, Vahidi Y, Fakhimi M, Asadollahpour A, *Erfani N*, Faghieh Z. Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer. *Heliyon*. 2020;6(12):e05556. DOI: <https://doi.org/10.1016/j.heliyon.2020.e05556>
25. Shiri Z, Mansouri R, Haghshenas MR, Talei A, *Erfani N**. FOXP3 genetic variation at position -2383 C/T (rs3761549) in patients with breast cancer. *Middle East Journal of Cancer*. 2019;10(4). DOI: <https://doi.org/10.30476/MEJC.2019.78638>
26. Rezaeifard S, Safaei A, Talei A, Faghieh Z, *Erfani N**. NK, NKT and Invariant-NKT Cells in Tumor Draining Lymph Nodes of Patients with Breast Cancer. *Iran J Immunol*. 2019;16(4):291-8. DOI: <https://doi.org/10.22034/IJI.2019.80280>
27. Hajighahramani N, Eslami M, Negahdaripour M, Ghoshoon MB, Dehshahri A, *Erfani N*, et al. Computational design of a chimeric epitope-based vaccine to protect against *Staphylococcus aureus* infections. *Mol Cell Probes*. 2019;46:101414. DOI: <https://doi.org/10.1016/j.mcp.2019.06.004>
28. Mohammadipour K, Mansouri R, Salmanpour R, Haghshenas MR, *Erfani N**. Investigation of Interleukin-17 Gene Polymorphisms and Serum Levels in Patients with Basal Cell Carcinoma of the Skin. *Iran J Immunol*. 2019;16(1):53-61. DOI: <https://doi.org/10.22034/IJI.2019.39406>
29. Jaafari-Ashkvandi Z, Shirazi SY, Rezaeifard S, Hamed A, *Erfani N**. Cytotoxic Effects of *Pistacia Atlantica* (Baneh) Fruit Extract on Human KB Cancer Cell Line. *Acta Medica (Hradec Kralove)*. 2019;62(1):30-4. DOI: <https://doi.org/10.14712/18059694.2019.43>
30. Fouladseresht H, Ziaee SM, *Erfani N*, Doroudchi M. Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma. *Asian Pac J Cancer Prev*. 2019;20(3):751-6. DOI: <https://doi.org/10.31557/APJCP.2019.20.3.751>

31. Fathi F, Faghieh Z, Khademi B, Kayedi T, **Erfani N***, Ghaderi A. PD-1 Haplotype Combinations and Susceptibility of Patients to Squamous Cell Carcinomas of Head and Neck. *Immunol Invest*. 2019;48(1):1-10. DOI: <https://doi.org/10.1080/08820139.2018.1538235>
32. Faghieh Z, Abtahi S, Khademi B, Nikfarjam F, **Erfani N***. Association of OX40 gene polymorphisms (rs17568G/A and rs229811A/C) with head and neck squamous cell carcinoma. *Mol Biol Rep*. 2019;46(3):2609-16. DOI: <https://doi.org/10.1007/s11033-019-04602-3>
33. Dorosti H, Eslami M, Negahdaripour M, Ghoshoon MB, Gholami A, Heidari R, Heidari, R. Dehshahri, A. **Erfani, N.** et al. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine. *J Biomol Struct Dyn*. 2019;37(13):3524-35. DOI: <https://doi.org/10.1080/07391102.2018.1519460>
34. Vakili B, Nezafat N, Hatam GR, Zare B, **Erfani N**, Ghasemi Y. Proteome-scale identification of Leishmania infantum for novel vaccine candidates: A hierarchical subtractive approach. *Comput Biol Chem*. 2018;72:16-25. DOI: <https://doi.org/10.1016/j.compbiolchem.2017.12.008>
35. Vakili B, Eslami M, Hatam GR, Zare B, **Erfani N**, Nezafat N, et al. Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. *Int J Biol Macromol*. 2018;120(Pt A):1127-39. DOI: <https://doi.org/10.1016/j.ijbiomac.2018.08.125>
36. Sarvari J, Dowran R, Hosseini SY, Fattahi MR, **Erfani N***. Association of PD-1 gene with outcome of hepatitis C virus infection. *EXCLI J*. 2018;17:935-44. DOI: <https://doi.org/10.17179/excli2018-1394>
37. Pirdelkhosh Z, Kazemi T, Haghshenas MR, Ghayumi MA, **Erfani N***. Investigation of programmed cell death-1 (PD-1) gene variations at positions PD1.3 and PD1.5 in Iranian patients with non-small cell lung cancer. *Middle East Journal of Cancer*. 2018;9(1):13-7. URL: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039860009&partnerID=40&md5=cff3d213c27aeb790bb8d4bc4be01993>
38. Negahdaripour M, Nezafat N, Eslami M, Ghoshoon MB, Shoolian E, Najafipour, S. Morowvat, M. H, Dehshahri, A., **Erfani, N.**, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. *Infect Genet Evol*. 2018;58:96-109. DOI: <https://doi.org/10.1016/j.meegid.2017.12.008>
39. Faghieh Z, Deihimi S, Talei A, Ghaderi A, **Erfani N***. Analysis of T cell receptor repertoire based on Vbeta chain in patients with breast cancer. *Cancer Biomark*. 2018;22(4):733-45. DOI: <https://doi.org/10.3233/CBM-181295>
40. Rashidi M, Seghatoleslam A, Namavari M, Amiri A, Fahmidehkar MA, Ramezani A, Eftekhari E, Hosseini A, **Erfani N**, et al. Selective Cytotoxicity and Apoptosis-Induction of Cyrtopodion scabrum Extract Against Digestive Cancer Cell Lines. *International Journal of Cancer Management*. 2017;10(5). DOI: <https://doi.org/10.5812/ijcm.8633>
41. Negahdaripour M, Eslami M, Nezafat N, Hajjighahramani N, Ghoshoon MB, Shoolian E, Dehshahri A, **Erfani N**, et al. A novel HPV prophylactic peptide vaccine, designed

by immunoinformatics and structural vaccinology approaches. *Infect Genet Evol.* 2017;54:402-16. DOI: <https://doi.org/10.1016/j.meegid.2017.08.002>

42. Menezes J, Edraki N, Kamat SP, Khoshneviszadeh M, Kayani Z, Mirzaei HH, Miri R, **Erfani N**, et al. Long Chain Alkyl Esters of Hydroxycinnamic Acids as Promising Anticancer Agents: Selective Induction of Apoptosis in Cancer Cells. *J Agric Food Chem.* 2017;65(33):7228-39. DOI: <https://doi.org/10.1021/acs.jafc.7b01388>
43. Haghshenas MR, Ashraf MJ, Khademi B, Ghaderi A, **Erfani N**, Razmkhah M. Chemokine and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7. *Eur Cytokine Netw.* 2017;28(1):27-35. DOI: <https://doi.org/10.1684/ecn.2017.0388>
44. Namavar Jahromi F, Samadi M, Mojtahedi Z, Haghshenas MR, Taghipour M, **Erfani N***. Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients. *Immunol Invest.* 2017; 46(5):469-80. DOI: <https://doi.org/10.1080/08820139.2017.1296858>
45. Haghshenas MR, Dabbaghmanesh MH, Miri A, Ghaderi A, **Erfani N***. Association of PDCD1 gene markers with susceptibility to thyroid cancer. *J Endocrinol Invest.* 2017;40(5):481-6. DOI: <https://doi.org/10.1007/s40618-016-0579-5>
46. Yadegari ZS, Akrami H, Hosseini SV, **Erfani N**. miR-146a gene polymorphism and susceptibility to gastric cancer. *Br J Biomed Sci.* 2016:1-3. DOI: <https://doi.org/10.1080/09674845.2016.1233790>
47. Shahsavani MB, Ahmadi S, Aseman MD, Nabavizadeh SM, Rashidi M, Asadi Z, **Erfani N**, et al. Anticancer activity assessment of two novel binuclear platinum (II) complexes. *J Photochem Photobiol B.* 2016;161:345-54. DOI: <https://doi.org/10.1016/j.jphotobiol.2016.05.025>
48. Khademi B, Tajvarpour M, Mojtahedi Z, Haghshenas MR, **Erfani N***. T-helper Type 1 and 2 Cytokine Levels in Patients with Benign and Malignant Salivary Gland Tumors. *Iran J Immunol.* 2016;13(1):9-15. DOI: <https://doi.org/10.1111/odi.12496>
49. Haghshenas MR, Khademi B, Ashraf MJ, Ghaderi A, **Erfani N***. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. *Oral Dis.* 2016;22(6):566-72. DOI: <https://doi.org/10.1111/odi.12496>
50. Firouzabadi N, Ghazanfari N, Alavi Shoushtari A, **Erfani N**, Fathi F, Bazrafkan M, et al. Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study. *PLoS One.* 2016;11(4):e0153667. DOI: <https://doi.org/10.1371/journal.pone.0153667>
51. Faghhih Z, Shobeiri SS, Ariaifar A, Sarkarian M, Zeighami S, Nazari N, Abbasi-Sarvak S, **Erfani N***. CD8+ T Lymphocyte Subsets in Bladder Tumor Draining Lymph Nodes. *Iran J Immunol.* 2016;13(4):237-48. DOI: <https://doi.org/10.1111/odi.12496>
52. Ebrahimi N, Rasoul-Amini S, Niazi A, **Erfani N**, Moghadam A, Ebrahiminezhad A, et al. Cytotoxic and Apoptotic Effects of Three Types of Silver-Iron Oxide Binary

Hybrid Nanoparticles. *Curr Pharm Biotechnol.* 2016;17(12):1049-57. DOI: <https://doi.org/10.2174/1389201017666160907143807>

53. Bahramali E, Firouzabadi N, Yavarian I, Shayesteh MR, **Erfani N**, Shoushtari AA, et al. Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial. *Eur J Clin Pharmacol.* 2016;72(9):1059-64. DOI: <https://doi.org/10.1007/s00228-016-2079-0>
54. Erfani N, Fattahi MJ, Dabbaghmanesh MH, Mehrazmay M, Monabati A, Kazerouni AR, **Erfani N**, et al. Dysregulated expression of Tensin 2 and components of the PI3 Kinase/Akt signaling pathway in human thyroid Carcinoma. *Middle East Journal of Cancer.* 2016;7(1):1-7. URL: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006208106&partnerID=40&md5=46c0c01243c022efb19dbd397e1acb4a>
55. Mortazavi SMJ, **Erfani N***, Mozdarani H, Azmoonfar R, Shokrpour N. Induction of apoptosis by 900 MHz radiofrequency radiation emitted from a GSM mobile phone simulator in bystander jurkat cells. *Iranian Journal of Radiation Research.* 2015;13(2):181-6. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84941640870&partnerID=40&md5=467eeeb9fd1b3d898e234973dcaffd35>
56. Mahmoudvand S, Safaei A, **Erfani N**, Sarvari J. Presence of Human Papillomavirus DNA in Colorectal Cancer Tissues in Shiraz, Southwest Iran. *Asian Pac J Cancer Prev.* 2015;16(17):7883-7. DOI: <https://doi.org/10.7314/apjcp.2015.16.17.7883>
57. Khodadad M, Hosseini SY, Shenavar F, **Erfani N**, Bina S, Ahmadian S, et al. Construction of expressing vectors including melanoma differentiation-associated gene-7 (Mda-7) fused with the rgd sequences for better tumor targeting. *Iranian Journal of Basic Medical Sciences.* 2015;18(8):780-7. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26557967>
58. Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, **Erfani N***. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. *Immunol Lett.* 2015;164(2):109-16. DOI: <https://doi.org/10.1016/j.imlet.2015.02.008>
59. Fazelzadeh Haghighi M, Ghayumi MA, Behzadnia F, **Erfani N***. Investigation of FOXP3 genetic variations at positions -2383 C/T and IVS9+459 T/C in southern iranian patients with lung carcinoma. *Iranian Journal of Basic Medical Sciences.* 2015;18(5):465-71. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84930354812&partnerID=40&md5=555ec57ef81f482cfd7698680519c86d>
60. Farhadi T, Nezafat N, Ghasemi Y, Karimi Z, Hemmati S, **Erfani N**. Designing of Complex Multi-epitope Peptide Vaccine Based on Omps of Klebsiella pneumoniae: An In Silico Approach. *Int J Pept Res Ther.* 2015;21(3):325-41. DOI: <https://doi.org/10.1007/s10989-015-9461-0>
61. **Erfani N**, Nazemosadat Z, Moein M. Cytotoxic activity of ten algae from the Persian Gulf and Oman Sea on human breast cancer cell lines; MDA-MB-231, MCF-7, and T-47D. *Pharmacognosy Res.* 2015;7(2):133-7. DOI: <https://doi.org/10.4103/0974-8490.150539>
62. Bina S, Shenavar F, Khodadad M, Haghshenas MR, Mortazavi M, Fattahi MR, **Erfani N**, et al. Impact of RGD peptide tethering to IL24/mda-7 (melanoma

differentiation associated gene-7) on apoptosis induction in hepatocellular carcinoma cells. *Asian Pac J Cancer Prev.* 2015;16(14):6073-80. DOI: <https://doi.org/10.7314/APJCP.2015.16.14.6073>

63. Abdolahi F, Dabbaghmanesh MH, Haghshenas MR, Ghaderi A, **Erfani N***. A gene-disease association study of IL18 in thyroid cancer: genotype and haplotype analyses. *Endocrine.* 2015;50(3):698-707. DOI: <https://doi.org/10.1007/s12020-015-0623-9>
64. Naeimi S, **Erfani N**, Ardekani AM, Ghaderi A. Variation of IL-17A and IL-17F genes in patients with breast cancer in a population from southern Iran (Running title: IL-17 gene polymorphisms and breast cancer). *Advances in Environmental Biology.* 2014;8(9 SPEC. ISSUE 4):892-7. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84940305790&partnerID=40&md5=65f783881e8f0bd4b773b13a34cd0b72>
65. Amidzadeh Z, Behbahani AB, **Erfani N**, Sharifzadeh S, Ranjbaran R, Moezi L, et al. Assessment of Different Permeabilization Methods of Minimizing Damage to the Adherence Cells for Detection of Intracellular RNA by Flow Cytometry. *Avicenna J Med Biotech.* 2014;6(1):38-46. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24523954>
66. Tavakkoli M, Miri R, Jassbi AR, **Erfani N**, Asadollahi M, Ghasemi M, et al. Carthamus, Salvia and Stachys species protect neuronal cells against oxidative stress-induced apoptosis. *Pharm Biol.* 2014;52(12):1550-7. DOI: <https://doi.org/10.3109/13880209.2014.908394>
67. **Erfani N**, Ahrari S, Ahrari I, Hosseini SV. CCR4 C1014T and CCL22 C16A Genetic Variations in the Iranian Patients with Colorectal Adenocarcinoma. *Iran J Allergy Asthma Immunol.* 2014;13(6):440-6. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25148803>
68. Sarvari J, Mojtahedi Z, Kuramitsu Y, Fattahi MR, Ghaderi A, Nakamura K, **Erfani N***. Comparative Proteomics of Sera From HCC Patients With Different Origins. *Hepatitis monthly.* 2014 Jan;14(1):e13103. DOI: <https://doi.org/10.5812/hepatmon.13103>
69. Zangeneh Z, Golmoghaddam H, Emad M, **Erfani N**, Doroudchi M. Elevated PD-1 expression and decreased telomerase activity in memory T cells of patients with symptomatic Herpes Zoster infection. *Cell Mol Biol (Noisy-le-grand).* 2014;60(4):13-21. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25399082>
70. **Erfani N**, Hamed-Shahraki M, Rezaeifard S, Haghshenas M, Rasouli M, Samsami Dehaghani A. FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer. *Iran J Immunol.* 2014;11(2):105-12. DOI: <https://doi.org/IJIV11i2A5>
71. **Erfani N**, Nedaei Ahmadi AS, Ghayumi MA, Mojtahedi Z. Genetic Polymorphisms of CCL22 and CCR4 in Patients with Lung Cancer. *Iranian journal of medical sciences.* 2014;39(4):367-73. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25031489>
72. Faghih Z, **Erfani N[#]**, Haghshenas MR, Safaei A, Talei AR, Ghaderi A. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. *Immunol Lett.* 2014;158(1-2):57-65. DOI: <https://doi.org/10.1016/j.imlet.2013.11.021>

73. Mojtahedi Z, Khademi B, **Erfani N**, Taregh Y, Rafati Z, Malekzadeh M, et al. Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma. *Indian J Cancer*. 2014;51(3):227-30. DOI: <https://doi.org/10.4103/0019-509x.146728>
74. Faghieh Z, Rezaeifard S, Safaei A, Ghaderi A, **Erfani N***. IL-17 and IL-4 Producing CD8+ T Cells in Tumor Draining Lymph Nodes of Breast Cancer Patients: Positive Association with Tumor Progression. *Iran J Immunol*. 2013 Dec;10(4):193-204. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84924918529&partnerID=40&md5=11ab1eee0c87716ae5f783f0b99dc67b>
75. Mojtahedi Z, **Erfani N***, Haghshenas MR, Hosseini SV, Ghaderi A. Association of FoxP3/Scurfin germline polymorphism (C-2383T/rs3761549) with colorectal cancer. *Annals of colorectal diseases*. 2013;1(1):12-6. DOI: <https://doi.org/10.5812/acr.11478>
76. Yousefi AR, Karimi MH, Shamsdin SA, Mehrabani D, Hosseini SV, **Erfani N**, et al. Investigation of PD1 gene polymorphisms in a group of Iranian patients with colorectal cancer. *Lab Medicine*. 2013;44(3):241-4. URL: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039860009&partnerID=40&md5=cff3d213c27aeb790bb8d4bc4be01993>
77. Dehaghani AS, Karimaghaei N, Parsanezhad ME, Malekzadeh M, Mehrzmay M, **Erfani N***. Anti nuclear antibodies in patients with polycystic ovary syndrome pre and post laparoscopic electrocauterization. *IJMS*. 2013 Jun;38(2 Suppl):187-90. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24031110>
78. **Erfani N**, Khademi B, Haghshenas MR, Mojtahedi Z, Khademi B, Ghaderi A. Intracellular CTLA4 and Regulatory T Cells in Patients with Laryngeal Squamous Cell Carcinoma. *Immunol Invest*. 2013 Dec 19;42(2):81-90. PubMed PMID: 23252863. DOI: <https://doi.org/10.3109/08820139.2012.708376>
79. Farjadian S, Rahimifar S, **Erfani N**, Lotfi R. Effect of Thermal Stress on MICA/B Induction in a Human Liposarcoma Cell Line. *Iranian Journal of Immunology : IJI*. 2013 Mar;10(1):31-9. DOI: <https://doi.org/IJIV10i1A4>
80. Khandani M, Sedaghat T, **Erfani N**, Haghshenas MR, Khavasi HR. Synthesis, spectroscopic characterization, structural studies and antibacterial and antitumor activities of diorganotin complexes with 3-methoxysalicylaldehyde thiosemicarbazone. *Journal of Molecular Structure*. 2013;1037:136-43. DOI: <https://doi.org/10.1016/j.molstruc.2012.12.061>
81. Mojtahedi Z, **Erfani N**, Malekzadeh M, Haghshenas MR, Ghaderi A, Samsami Dehaghani A. HER2 Ile655Val Single Nucleotide Polymorphism in Patients with Ovarian Cancer. *Iranian Red Crescent medical journal*. 2013 Jan;15(1):1-3. PubMed PMID: 23487505. Pubmed Central PMCID: PMC3589767. DOI: <https://doi.org/10.5812/ircmj.2173>
82. Mohammadi-Samani S, Miri R, Salmanpour S, Khalighian N, Sotoudeh S, **Erfani N**. Preparation and assessment of chitosan-coated superparamagnetic Fe₃O₄ nanoparticles for controlled delivery of methotrexate. *Research in Pharmaceutical Sciences*. 2013;8(1):25-33. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24459473>

83. **Erfani N**, Haghshenas MR, Hoseini MA, Hashemi SB, Khademi B, Ghaderi A. Strong Association of CTLA-4 Variation (CT60A/G) and CTLA-4 Haplotypes with Predisposition of Iranians to Head and Neck Cancer. *Iranian journal of immunology: IJI*. 2012 Sep;9(3):188-98. PubMed PMID: 23023383. DOI: <https://doi.org/1JI9i3A5>
84. **Erfani N**, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). *Lung Cancer*. 2012 Aug;77(2):306-11. PubMed PMID: 22608141. DOI: <https://doi.org/10.1016/j.lungcan.2012.04.011>
85. **Erfani N**, Moghaddasi-Sani F, Razmkhah M, Haghshenas MR, Talei A, Ghaderi A. CCL22 16C/A Genetic Variation is not Associated with Breast Carcinoma in Southern Iranian Population. *Iranian journal of immunology : IJI*. 2012 Dec;9(4):226-33. PubMed PMID: 23268288. DOI: <https://doi.org/1JIv9i4A2>
86. Khaghanzadeh N, Mojtahedi Z, Ramezani M, **Erfani N**, Ghaderi A. Umbelliprenin is cytotoxic against QU-DB large cell lung cancer cell line but anti-proliferative against A549 adenocarcinoma cells. *DARU Journal of Pharmaceutical Sciences*. 2012;20(1):69. DOI: <https://doi.org/10.1186/2008-2231-20-69>
87. Mojtahedi Z, **Erfani N**, Ghaderi A. Comparative proteomics analysis of SKBR3 and MCF7 breast cancer cell lines using two dimensional electrophoresis: Ready to build postgenomics capacity for OMICS R&D in developing countries? *Current Pharmacogenomics and Personalized Medicine*. 2012;10(2):132-7. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-84861760613&partnerID=40&md5=e15333981e7c2713af4b1392aeb51ac3>
88. Mojtahedi Z, Mohmedi M, Rahimifar S, **Erfani N**, Hosseini SV, Ghaderi A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. *Gene*. 2012 Oct 25;508(2):229-32. PubMed PMID: 22892379. DOI: <https://doi.org/10.1016/j.gene.2012.07.059>
89. Razmkhah M, Jaberipour M, Safaei A, Talei AR, **Erfani N**, Ghaderi A. Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients. *European cytokine network*. 2012 Jul-Sep;23(3):72-7. PubMed PMID: 23078970. DOI: <https://doi.org/10.1684/ecn.2012.031>
90. Soltani MH, Kalantari T, Karimi MH, **Erfani N**, Kamali Sarvestani E. Evaluation of the immunomodulatory effect of curdlan on maturation and function of mouse spleen-derived dendritic cells. *Iranian journal of immunology: IJI*. 2012 Sep;9(3):168-74. PubMed PMID: 23023381. DOI: <https://doi.org/1JIv9i3A3>
91. Yousefipour GA, Haghshenas MR, Yahyazadeh S, **Erfani N**. Stromal cell derived factor-1 genetic variation at locus 801 in patients with myasthenia gravis. *Iranian journal of immunology: IJI*. 2011;8(2):90. DOI: <https://doi.org/1JIv8i2A4>
92. Razmkhah M, Jaberipour M, **Erfani N**, Habibagahi M, Talei A-r, Ghaderi A. Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-[beta]1 and upregulate expression of regulatory molecules on T cells: Do they

- protect breast cancer cells from the immune response? *Cellular Immunology*. 2011;266(2):116-22. DOI: <https://doi.org/10.1016/j.cellimm.2010.09.005>
93. Haghshenas M, Naeimi S, Talei A, Ghaderi A, **Erfani N**. Program death 1 (PD1) haplotyping in patients with breast carcinoma. *Molecular Biology Reports*. 2011;38(6):4205-10. DOI: <https://doi.org/10.1007/s11033-010-0542-z>
 94. **Erfani N**, Ghaderi A. Response to ctla-4 gene variations in southern Iranian patients with cervical cancer. *Gynecologic Oncology*. 2011;121(3):641-2. DOI: <https://doi.org/10.1016/j.ygyno.2011.01.035>
 95. Naeimi S, **Erfani N**, Solimanipoor M. Investigation of C-C Chemokine Receptor type 4 (CCR4) gene polymorphism in patients with Gestational Trophoblastic Diseases (GTD). *Armaghan Danesh*. 2011;16(3):262-71. Per.
 96. Naeimi S, **Erfani N**. Investigation of single nucleotide polymorphism of the CCL22 gene at position 16C/A in patients with gestational trophoblastic disease. *Journal of Birjand University of Medical Sciences*. 2011;18(2):86-93. Per.
 97. Naeimi S, Bagheri K, **Erfani N**. Cytotoxic T lymphocyte associated molecule -4 (CTLA-4) gene polymorphisms in ovarian cancer patients. *Behboud: Kermanshah University of Medical Sciences*. 2010;12(3):251-7. Per.
 98. Rahimifar S, **Erfani N**, Sarraf Z, Ghaderi A. ctla-4 gene variations may influence cervical cancer susceptibility. *Gynecol Oncol*. 2010;119(1):136-9. DOI: <https://doi.org/10.1016/j.ygyno.2010.06.006>
 99. **Erfani N**, Ghayumi MA, Ghaderi A. CTLA4 gene variations and haplotypes in patients with lung cancer. *Cancer Genet Cytogenet*. 2010;196(2):171-4. DOI: <https://doi.org/10.1016/j.cancergencyto.2009.09.001>
 100. **Erfani N**, Razmkhah M, Ghaderi A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. *Cancer Invest*. 2010;28(8):828-32. DOI: <https://doi.org/10.3109/07357901003630934>
 101. Yousefipour G, **Erfani N**, Momtahan M, Moghaddasi H, Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. *Acta Neurol Scand*. 2009;120(6):424-9. DOI: <https://doi.org/10.1111/j.1600-0404.2009.01177.x>
 102. Shayan S, Abdi AR, Zibaenezhad MJ, Haghshenas MR, **Erfani N**, Ghaderi A. Interleukin-18 gene polymorphism in patients with and without atherosclerotic coronary artery disease. *Iranian Cardiovascular Research Journal*. 2009;3(3):158-63. URL: <http://www.scopus.com/inward/record.url?eid=2-s2.0-73449091126&partnerID=40&md5=d5326035fdabb6eff79c6dce266f23c9>
 103. Farjadfar A, Mojtahedi Z, Ghayumi MA, **Erfani N**, Haghshenas MR, Ghaderi A. Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. *Acta Oncol*. 2009;48(7):971-6. DOI: <https://doi.org/10.1080/02841860902878145>

104. Faghih Z, **Erfani N**, Razmkhah M, Sameni S, Talei A, Ghaderi A. Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer. *Mol Biol Rep.* 2009;36(7):1923-8. DOI: <https://doi.org/10.1007/s11033-008-9400-7>
105. Khademi B, Razmkhah M, **Erfani N**, Gharagozloo M, Ghaderi A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. *Pathol Oncol Res.* 2008;14(1):45-50. DOI: <https://doi.org/10.1007/s12253-008-9007-2>
106. Ji H, **Erfani N**, Tauro BJ, Kapp EA, Zhu HJ, Moritz RL, et al. Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. *Electrophoresis.* 2008;29(12):2660-71. DOI: <https://doi.org/10.1002/elps.200800015>
107. Arandi N, Talei A, **Erfani N**, Ghaderi A. Intercellular adhesion molecule-1 genetic markers (+241G/A and +469A/G) in Iranian women with breast cancer. *Cancer Genet Cytogenet.* 2008;183(1):9-13. DOI: <https://doi.org/10.1016/j.cancergencyto.2008.01.019>
108. Hadinia A, Hossieni SV, **Erfani N**, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. *J Gastroenterol Hepatol.* 2007;22(12):2283-7. DOI: <https://doi.org/10.1111/j.1440-1746.2007.04862.x>
109. **Erfani N**, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. *Cancer Genet Cytogenet.* 2006;165(2):114-20. DOI: <https://doi.org/10.1016/j.cancergencyto.2005.07.020>
110. Almasi S, **Erfani N**, Mojtahedi Z, Rajaei A, Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. *Genes Immun.* 2006;7(5):401-6. DOI: <https://doi.org/10.1038/sj.gene.6364313>
111. Razmkhah M, Doroudchi M, Ghayumi SM, **Erfani N**, Ghaderi A. Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. *Lung Cancer.* 2005;49(3):311-5. DOI: <https://doi.org/10.1016/j.lungcan.2005.04.014>

Participation in Congresses and Symposiums

- More than 100 oral or poster presentations at international congresses
- Scientific Secretary of the Second National Symposium on “Immune cell Therapy”, 16 Feb 2017, Shiraz, Iran
- Member of the Scientific committee at:
 - the 1st International Student Congress on Cell & Molecular Medicine (ISCCMM) 17-19 Feb 2011, Shiraz, Iran
 - the 11th International Congress of Immunology & Allergy of Iran, April 26-29, 2012, Tehran, Iran
 - the 12th International Congress of Immunology & Allergy of Iran, April 29-May 2, 2014, Tehran, Iran
 - the 13th International Congress of Immunology & Allergy of Iran, April 2016, Tabriz, Iran

- the 14th International Congress of Immunology & Allergy of Iran, April 2018, Tehran, Iran
- the 15th International Congress of Immunology & Allergy of Iran, April 2021, Ahwaz, Iran
- the incoming 16th International Congress of Immunology & Allergy of Iran, to be held on April 2023, Tehran, Iran

Experiences and skills

Laboratoy Skills:

1. Expert in cell culture, Flowcytometry and several other immunological based techniques including: Immunohistochemistry, ELISA, IF (ANA), RIA, MLC, Proliferation assay, NK activity, HLA typing, and Immuno-electrophoresis
2. Expert in molecular based techniques including: DNA sequencig and bioinformatics anlaysis, Fragment-analysis, DHPLC, DNA extraction from blood and tissues, PCR (different types), RFLP, SSCP, SDS-PAGE, DNA PAG & Agarose Gel Electrophoresis
3. Proficint in HLA typnig, as well as, immunological consultation for donor selection befor hematologic stem cell transplantation (HSCT)
4. Expert in protein preparation for proteomics from hole cell lysate, cell secreted vesicles and body fluids, Western blothing, 2DE, 2DE-DIGE

Computer skills:

1. Proficient in **Bioinformatics** software packages, including: **DNAsisMax**, **Gene Runner**, **DNAsstar**, and **MASCOT** search engine
2. Proficient with Flowcytometric analysis using **CellQuest**, **CellQuest-Pro** and **FACS-DIVA** software pakages.
3. Expert in **Arlequin**; the software pakage for **population genetics** and haplotype analysis
4. Familiar with **Biostatistics** software packages, including: SPSS (both data assembly and analysis) and EpiInfo
5. Expert in **bibliography (reference managing)** software packages: "EndNote" and "Reference Manager"
6. Expert in **WebSite design** and management using IcarusPLus software pakage.

Workshops:

1. Holding and teaching at more that 80 workshops on "EndNote, bibliographic software package", for faculty members and/or graduate students, Medical universities around the county. 2008-now
2. Holding and teaching at more that 15 Workshop on "Flowcytoetry, basics and applications", for faculty members and/or post graduate students, Medical universities around the county. 2008-now
3. Holding and teaching at more that 5 Workshop on "DNA sequencing", faculty members and post graduate students, Medical universities around the county. 2010-now
4. Holding and teaching at more that 18 workshops on "Research Profiles and Scientific Social Networks", for faculty members and/or graduate students, Medical universities around the county. 2012-now

5. Teaching the “research methodology” to postgraduate students attending “Resident-as-a-teacher” workshops hold by EDC, Shiraz University of Medical Sciences, 2011-2012.

Hobbies

Swimming, Soccer, Poem, Music, Calligraphy, Movie

References

❖ **Richard J. Simpson, PhD**

Distinguished Professor of Biochemistry

Department of Biochemistry

La Trobe University

Melbourne Victoria 3086

Australia

Tell: +61-3-94793099

E-mail: Richard.Simpson@latrobe.edu.au

URL: <https://scholars.latrobe.edu.au/r2simpson>

❖ **Abbasali Ghaderi, PhD**

Distinguished Professor of immunology

Shiraz Institute for Cancer Research, Head

School of Medicine

Shiraz University of Medical Sciences

PO BOX: 71345-1798

Shiraz – Iran

Tel/: +98-71-32303678

Fax: +98-71-32304952

E-mail: ghadria@sums.ac.ir

❖ **Mehrnoosh Doroudchi, PhD**

Professor of Immunology and Microbiology

Department of immunology

School of Medicine

Shiraz University of Medical Sciences

Shiraz – Iran

Tel/Fax: +98-71-32351557

E-mail: mdoroud@sums.ac.ir